ISOFOL Isofol Medical AB (publ)

0.0976USD0.9900 SEK · STO+3.66%Mkt Cap: 31.29M USDP/E: —

Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in …

Key Statistics

Company
Market Cap31.29M USD
Enterprise Value21.62M USD
Revenue (TTM)—
Gross Profit-3.96M USD
Net Income (TTM)-5.34M USD
Revenue/Share—
Last Price0.0976 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees6
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0009581051
Valuation
P/E (Trailing)—
P/E (Forward)-19.80
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B3.82
EPS (TTM)-0.02 USD
EPS (Forward)-0.0049 USD
52W Range
0.054439% of range0.1657
52W High0.1657 USD
52W Low0.0544 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-50.22%
ROA-41.86%
ROIC—
ROCE-51.61%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.12M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-12.36%
Net Debt-9.67M USD
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity—
Current Ratio5.59
Quick Ratio5.51
Book Value/Sh0.03 USD
Cash/Share0.03 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)0.3575 USD
Upside (mean)+266.2%
Target Range0.1676 USD – 0.5473 USD
0.1676+266.2% to mean0.5473
# Analysts2
Ownership
Shares Out.320.49M
Float228.15M
Insiders26.07%
Institutions15.00%
Technical
SMA 500.0946 (+3.2%)
SMA 2000.0772 (+26.5%)
Beta1.29
S&P 52W Chg8.68%
Avg Vol (30d)2.24M
Avg Vol (10d)3.29M
Technical Indicators
RSI (14)44.7
MACD0.0048
MACD Signal0.0637
MACD Hist.-0.0590
BB Upper0.1551 USD
BB Middle0.1188 USD
BB Lower0.0825 USD
BB Width61.10%
ATR (14)0.0136 USD
Vol Ratio (20d)0.16x

About Isofol Medical (STO: ISOFOL)

›

Isofol Medical (STO: ISOFOL) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 6 employees.

The shares were at 0.9900 SEK on 20 November 2026, up 46.9% over 52 weeks. Its 52-week range is 0.5515 SEK to 1.680 SEK: the price is 41.1% below the high and 79.5% above the low.

Its market capitalisation is 317.29M SEK.

Isofol Medical reports return on equity of -50.2% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 98.09M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 2 analysts cover the stock; their mean price target of 3.625 SEK is 266.2% above the current price.